Ovarian cancer in the proteomics era

International Journal of Gynecological Cancer

Volumn 18, Issue SUPPL. 1, 2008, Pages 1-6

  Annunziata, C M ^a   Azad, N ^a   Dhamoon, A S ^a   Whiteley, G ^a   Kohn, E C ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Mass spectrometry; Ovarian cancer; Proteomics; Tissue microarray

Indexed keywords

PROTEOME;

ARTICLE; DILUTION; FEMALE; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN TISSUE; MASS SPECTROMETRY; MICRODISSECTION; OVARY CANCER; PRIORITY JOURNAL; PROTEIN MICROARRAY; PROTEOMICS; SENSITIVITY AND SPECIFICITY; SIGNAL TRANSDUCTION; TECHNOLOGY; VALIDATION PROCESS;

BLOOD CHEMICAL ANALYSIS; FEMALE; HUMANS; MASS SPECTROMETRY; OVARIAN NEOPLASMS; PROTEIN ARRAY ANALYSIS; PROTEOMICS;

EID: 40749124480     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1111/j.1525-1438.2007.01096.x     Document Type: Article

References (23)

1. Jemal A, Siegel R, Ward E et al. Cancer statistics 2006. CA Cancer J Clin 2006 56 : 106 30.
2. Davidson B, Espina V, Steinberg SM et al. Proteomic analysis of malignant ovarian cancer effusions as a tool for biologic and prognostic profiling. Clin Cancer Res 2006 12 (3 Pt 1 791 9.
3. Donninger H, Bonome T, Radonovich M et al. Whole genome expression profiling of advance stage papillary serous ovarian cancer reveals activated pathways. Oncogene 2004 23 : 8065 77.
4. Engwegen JY, Gast MC, Schellens JH, Beijnen JH. Clinical proteomics: searching for better tumour markers with SELDI-TOF mass spectrometry. Trends Pharmacol Sci 2006 27 : 251 9.
5. Jazaeri AA, Awtrey CS, Chandramouli GV et al. Gene expression profiles associated with response to chemotherapy in epithelial ovarian cancers. Clin Cancer Res 2005 11 : 6300 10.
6. Moore LE, Fung ET, McGuire M et al. Evaluation of apolipoprotein A1 and posttranslationally modified forms of transthyretin as biomarkers for ovarian cancer detection in an independent study population. Cancer Epidemiol Biomarkers Prev 2006 15 : 1641 6.
7. Petricoin EF, Ardekani AM, Hitt BA et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002 359 : 572 7.
8. Stewart JJ, White JT, Yan X et al. Proteins associated with cisplatin resistance in ovarian cancer cells identified by quantitative proteomic technology and integrated with mRNA expression levels. Mol Cell Proteomics 2006 5 : 433 43.
9. Barker PE, Wagner PD, Stein SE, Bunk DM, Srivastava S, Omenn GS. Standards for plasma and serum proteomics in early cancer detection: a needs assessment report from the national institute of standards and technology - National Cancer Institute Standards, Methods, Assays, Reagents and Technologies Workshop. August 18-19, 2005. Clin Chem 2006 52 : 1669 74.
10. Engwegen JY, Helgason HH, Cats A et al. Identification of serum proteins discriminating colorectal cancer patients and healthy controls using surface-enhanced laser desorption ionisation-time of flight mass spectrometry. World J Gastroenterol 2006 12 : 1536 44.
11. Kopec KK, Bozyczko-Coyne D, Williams M. Target identification and validation in drug discovery: the role of proteomics. Biochem Pharmacol 2005 69 : 1133 9.
12. Posadas EM, Simpkins F, Liotta LA, MacDonald C, Kohn EC. Proteomic analysis for the early detection and rational treatment of cancer-realistic hope? Ann Oncol 2005 16 : 16 22.
13. Rogers MA, Clarke P, Noble J et al. Proteomic profiling of urinary proteins in renal cancer by surface enhanced laser desorption ionization and neural-network analysis: identification of key issues affecting potential clinical utility. Cancer Res 2003 63 : 6971 83.
14. Sauter ER, Shan S, Hewett JE, Speckman P, Du Bois GC. Proteomic analysis of nipple aspirate fluid using SELDI-TOF-MS. Int J Cancer 2005 114 : 791 6.
15. Simpkins F, Czechowicz JA, Liotta L, Kohn EC. SELDI-TOF mass spectrometry for cancer biomarker discovery and serum proteomic diagnostics. Pharmacogenomics 2005 6 : 647 53.
16. Petricoin EF, Zoon KC, Kohn EC, Barrett JC, Liotta LA. Clinical proteomics: translating benchside promise into bedside reality. Nat Rev Drug Discov 2002 1 : 683 95.
17. Posadas EM, Kwitkowski V, Kotz HL et al. A prospective analysis of imatinib-induced c-kit modulation in ovarian cancer: a phase II clinical study with proteomic profiling. Cancer 2007 110 : 309 17.
18. Posadas EM, Liel MS, Kwitkowski V et al. A phase II and pharmacodynamic study of gefitinib in patients with refractory or recurrent epithelial ovarian cancer. Cancer 2007 109 : 1323 30.
19. Belluco C, Petricoin EF, Mammano E et al. Serum proteomic analysis identifies a highly sensitive and specific discriminatory pattern in stage 1 breast cancer. Ann Surg Oncol 2007 14 : 2470 6.
20. Ransohoff DF. Lessons from controversy: ovarian cancer screening and serum proteomics. J Natl Cancer Inst 2005 97 : 315 9.
21. Petricoin EF III., Ornstein DK, Paweletz CP et al. Serum proteomic patterns for detection of prostate cancer. J Natl Cancer Inst 2002 94 : 1576 8.
22. Zhang Z, Bast RC Jr., Yu Y et al. Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res 2004 64 : 5882 90.
23. Paweletz CP, Charboneau L, Bichsel VE et al. Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front. Oncogene 2001 20 : 1981 9.